References
- Maj J, Rogoz Z, Skuza G, Kolodziejczyk K: The behavioural effects of pramipexole, a novel dopamine receptor agonist. Fur J Pharmacol 1997; 324(1):31–37
- Maj I, Rogoz Z, Skuza G, Kolodziejczyk K: Antidepressant effects of pramipexole, a novel dopamine receptor agonist. J Neural Transm 1997; 104(4-5):525–533
- Willner P: The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol 1997; 12(3, suppl):S7—S14
- Corrigan MH, Denahan AQ, Wright EC, Ragual, RI, Evans DL: Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depression and Anxiety 2000; 11:58–65
- Piercey MF: Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol 1998; 21(3):141–151
- Szegedi A, Hillert A, Wetzel H, Klieser E, Gaebel W, Benkert 0: Pramipexole, a dopamine agonist, in major depression: Antidepressant effects and tolerability in an open-label study with multiple doses. Clinical Neuropharmacology 1997; 20(1, suppl):S36—S45
- Goldberg J, Frye M, Dunn R: Pramipexole in refractory bi-polar depression. Am J Psychiatry 1999; 156(5):798
- Oertel W: Toward a new paradigm in the treatment of Parkin-son's disease. Clin Neuropharmacol 1997; 20(1, suppl):S1—S2
- Caskey NH, Jarvik ME, Wirshing WC: The effects of dopa-minergic D2 stimulation and blockade on smoking behavior. Exp Clin Psychopharmacol 1999; 7(1):72–78
- Frucht S. Rogers JD, Greene PE, Gordon MF, Fahn S: Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 52(9):1908–1910